Search results
Results From The WOW.Com Content Network
Learn about Lilly's pipeline, including information about our investigational molecules and potential indication data.
The Investor Relations website contains information about Eli Lilly and Company's business for stockholders, potential investors, and financial analysts.
Cancer. We are expanding a portfolio of programs based on high biologic conviction to give people living with cancer more options. Our early-stage molecules under investigation include a KRAS G12C inhibitor, Next-Gen RET inhibitor and PI3Kα inhibitor. Learn More About Our Work in Cancer.
Lilly is providing new biomarker data from donanemab from the phase 2 TRAILBLAZER-ALZ study. Lilly initiated a rolling submission for donanemab to the FDA for accelerated approval in early Alzheimer's disease, which it expects to complete in the coming months, likely by the end of the first quarter.
Chris Schott has given his Buy rating due to a combination of factors including the expected significant growth of Eli Lilly & Co’s (LLY) products and the company’s strong pipeline.
Pipeline progress included FDA approval of Zepbound for adults with obesity or overweight with weight-related comorbidities and Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma under the Accelerated Approval Program.
In 2023, we’re building on this momentum with the potential to launch as many as 2022 was an exciting year for Lilly, driven by significant pipeline progress and expanded use of our medicines, as we reached more people and communities around the world.
ELI LILLY AND COMPANY 2021 Pipeline Highlights Diabetes & Obesity Building on our history in diabetes, we’ve expanded our strategic focus to develop medicines that disrupt the disease cascade caused by obesity and type 2 diabetes progression. In 2021, we submitted regulatory applications in the U.S., Europe, Japan and several
Lilly is executing very well in selling recently launched drugs and developing its pipeline, a key element in its wide moat.
We’re a medicine company turning science into healing to make life better for people around the world. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing science to solve some of the world's most significant health challenges.